Prelude Therapeutics Incorporated
PRLDHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Prelude Therapeutics Incorporated focuses on Biotechnology services and products. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. At a $312.2M market cap, Prelude Therapeutics Incorporated ranks as a small-cap company within healthcare. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Market Cap
$312.2M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-4.17
EPS (TTM)
$-1.00
EPS (Fwd)
$-0.94
ROE
-95.3%
ROA
-39.7%
Cash
$81.6M
Total Debt
$17.7M
Free CF
-$17.9M
52W Change
332.2%
Annual Financials
Cash vs Debt
With $81.6M in cash and $17.7M in debt, PRLD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$17.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -95.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PRLD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.